Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gain Therapeutics Inc (NQ: GANX ) 1.270 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Gain Therapeutics Inc < Previous 1 2 3 4 5 Next > Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Today 8:35 EDT Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference June 25, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M June 18, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Gain Therapeutics: Q4 Earnings Insights March 26, 2024 Via Benzinga S&P 500 Edges Lower; RH Shares Plunge After Q1 Results June 14, 2024 Via Benzinga Topics Stocks Exposures US Equities Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session June 14, 2024 Via Benzinga Gold Gains 1%; US Consumer Sentiment Falls In June June 14, 2024 Via Benzinga Dear ARM Stock Fans, Mark Your Calendars for June 24 June 14, 2024 Arm stock is up on Friday and is preparing for a catalyst later this month when it replaces Sirius XM on the Nasdaq 100. Via InvestorPlace Dow Tumbles Over 200 Points; Adobe Earnings Top Views June 14, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Is Gain Therapeutics (GANX) Stock Down 25% Today? June 14, 2024 Gain Therapeutics stock is down on Friday after the company priced an $11 million public offering for roughly 7 million shares of GANX. Via InvestorPlace Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket June 14, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session June 14, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday June 14, 2024 Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning! Via InvestorPlace Gain Therapeutics Announces Pricing of $11.0 Million Public Offering June 13, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Proposed Public Offering June 13, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 30, 2024 Via Benzinga Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 May 30, 2024 New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s disease From Gain Therapeutics, Inc. Via GlobeNewswire GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024 May 14, 2024 GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update May 14, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease April 24, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer April 08, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying April 02, 2024 The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Topics Stocks Exposures US Equities Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer April 01, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023 March 26, 2024 GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update March 26, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics to Present at Public Ventures Discovery Day March 15, 2024 Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb... From Gain Therapeutics, Inc. Via GlobeNewswire Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease March 05, 2024 Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction From Gain Therapeutics, Inc. Via GlobeNewswire EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease March 05, 2024 Gain Therapeutics' GBA1 Parkinson's disease focused GT-02287's mechanism of action, tackling GCase misfolding to enhance lysosomal activity. Via Benzinga Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease February 27, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.